IFRX · InflaRx N.V.
Market Cap
$278.53M
Shares
147.37M
Volume · Oct 5
701.01K
Avg daily vol (3M)
819.03K
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$1.68
Open$1.70
Day$1.65–1.72
52W close$0.83–2.74
Avg vol 30d680K
Short int12.1M · 8.2% float · 23.1d
Short vol51%
DataJan 2020–Oct 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
—
Trailing 12 months
Revenue growth YoY
+520.3%
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+21.8%
Year over year · more shares
Price change (1Y)
+24.6%
Trailing year
Short interest
8.2%
Latest settlement · 23.1 days to cover
Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Neutral
Momentum
Strong
Sentiment
Bullish
Fundamentals
Limited
Quant / Vol
Very High
Market backdrop
VIX 15.5 · calm
Equity put/call 0.59
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+6%
above
Price vs 50-day avg
−16%
below
RSI (14)
31
neutral
MACD trend
Negative
52-week position
45%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−24%
trailing
6-month return
+47%
trailing
YTD return
+66%
this year
Relative strength
+36%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $2 › 200d $2 — 50d above 200d
Institutional flow
Accumulating
+72% holders QoQ · +29 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
8.22% of float · ▼ -1.6% MoM · 23.1 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
62 holders — near 3-yr high, broad support
Squeeze score
59
elevated · 0–100
Fundamentals
Not enough data for a confident read.
Quant / Vol
risk profile
Volatility
98%
annualized · 1-yr
Max drawdown
−50%
past year
ATR
7.6%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+6%
Bullish
Price vs 50-day avg
−16%
Bearish
RSI (14)
31
Neutral
MACD trend
Negative
Bearish
52-week position
45%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross)
No cross
50d $2 › 200d $2 — 50d above 200d
Institutional flow
Accumulating
+72% holders QoQ · +29 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
8.22% of float · ▼ -1.6% MoM · 23.1 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
62 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $1
Now $2 · 45%
Range high $3
vs 200-day avg +6%
vs 50-day avg -16%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
IFRX
this stock
InflaRx N.V.
|
$278.53M | +66.3% | — | — | 8.2% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$133.37B | +11.1% | +46.2% | 30.7 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$81.13B | -5.9% | +20.8% | 19.5 | 2.5% |
|
MRNA
Moderna, Inc.
|
$79.40B | +589.1% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$61.25B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| IFRX | -7.7% | -24.3% | +47.4% | -6.7% | +66.3% |
| SPY | +1.2% | +0.6% | +11.6% | +1.6% | +13.6% |
| vs SPY | -8.9% | -24.9% | +35.8% | -8.3% | +52.7% |